Robert Hawkins, MA MB BS PhD FRCP

Search results

• 2022

  Acute and chronic cardiopulmonary effects of high dose interleukin-2 therapy: an observational magnetic resonance imaging study

  Lagan, J., Naish, J. H., Campbell, C., Chow, S., Pillai, M., Bradley, J., Francis, L., Clark, D., Macnab, A., Dobson, R., Schelbert, E. B., Schmitt, M., Hawkins, R. & Miller, C. A., 24 May 2022, (Accepted/In press) In: Diagnostics.

  Research output: Contribution to journal › Article › peer-review

  • Interleukin 2 100%
  • Drug Megadose 36%
  • Cardiomyocyte 27%
  • Patient 18%
  • Left Ventricular Hypertrophy 18%

• Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma

  Pillai, M., Jiang, Y., Lorigan, P. C., Thistlethwaite, F. C., Thomas, M., Kirillova, N., Bridgeman, J. S., Kueberuwa, G., Biswas, S., Velazquez, P., Chonzi, D., Guest, R. D., Roberts, Z. J. & Hawkins, R. E., 2022, In: American journal of cancer research. 12, 8, p. 3967-3984 18 p.

  Research output: Contribution to journal › Article › peer-review

  • Patient 100%
  • Tumor Infiltrating Lymphocyte 100%
  • Tumor-Infiltrating Lymphocytes 100%
  • Therapeutic Procedure 63%
  • Diseases 45%
• 2021

  Clinical Feasibility and Treatment Outcomes with Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients with Advanced Cutaneous Melanoma.

  Hawkins, R. E., Jiang, Y., Lorigan, P. C., Thistlethwaite, F. C., Pillai, M., Thomas, M., Kirilova, N., Bridgeman, J. S., Kueberuwa, G., Guest, R. S. & Roberts, Z. J., Jul 2021, In: Cancer Research. 81, 13

  Research output: Contribution to journal › Meeting Abstract › peer-review
• 2020

  Massively parallel interrogation and mining of natively paired human TCRαβ repertoires

  Spindler, M. J., Nelson, A. L., Wagner, E. K., Oppermans, N., Bridgeman, J. S., Heather, J. M., Adler, A. S., Asensio, M. A., Edgar, R. C., Lim, Y. W., Meyer, E. H., Hawkins, R. E., Cobbold, M. & Johnson, D. S., 16 Mar 2020, In: Nature biotechnology. 38, 5, p. 609-619 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • T Cell Receptor 100%
  • Sample 11%
  • Cells 11%
  • Screening 11%
  • Antigen Specificity 11%
• 2019

  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

  Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H., & 12 othersBedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., 15 Jun 2019, In: The Lancet. 393, 10189, p. 2404-2415 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Bevacizumab 100%
  • Atezolizumab 100%
  • Sunitinib 90%
  • Patient 70%
  • Therapeutic Procedure 50%

• Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

  Schmidinger, M., Bamias, A., Procopio, G., Hawkins, R., Sanchez, A. R., Vázquez, S., Srihari, N., Kalofonos, H., Bono, P., Pisal, C. B., Hirschberg, Y., Dezzani, L., Ahmad, Q. & Jonasch, E., 2019, In: Oncologist.

  Research output: Contribution to journal › Article › peer-review

  • Pazopanib 100%
  • Patient 88%
  • Clinical Trial 88%
  • Inpatient 66%
  • Observational Study 66%

• Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy

  Hall, P. E., Shepherd, S. T. C., Brown, J., Larkin, J., Jones, R., Ralph, C., Hawkins, R., Chowdhury, S., Boleti, E., Bahl, A., Fife, K., Webb, A., Crabb, S. J., Geldart, T., Hill, R., Dunlop, J., McLaren, D., Ackerman, C., Wimalasingham, A., Beltran, L., & 2 othersNathan, P. & Powles, T., 2019, In: European Urology Focus.

  Research output: Contribution to journal › Article › peer-review

  • Lesion 100%
  • Inpatient 66%
  • Patient 50%
  • Diseases 50%
  • Cancer Staging 50%
• 2018

  A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

  Kueberuwa, G., Zheng, W., Kalaitsidou, M., Gilham, D. & Hawkins, R., 2018, In: Journal of Visualized Experiments. 140

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptor T-Cell 100%
  • Mouse 44%
  • CD19 44%
  • Enalapril Maleate 33%
  • B Cell 33%

• Ex vivo expanded Tumour Infiltrating Lymphocytes (TILs) from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells

  Owens, G., Price, M., Cheadle, E., Hawkins, R., Gilham, D. & Edmondson, R., Oct 2018, In: Cancer Immunology, Immunotherapy.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Infiltrating Lymphocyte 100%
  • Neoplasm 85%
  • Krukenberg Tumor 57%
  • Patient 42%
  • Ovarian Tumor 42%
• 2017

  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial

  Chamie, K., Donin, N. M., Klöpfer, P., Bevan, P., Fall, B., Wilhelm, O., Störkel, S., Said, J., Gambla, M., Hawkins, R. E., Jankilevich, G., Kapoor, A., Kopyltsov, E., Staehler, M., Taari, K., Wainstein, A. J. A., Pantuck, A. J. & Belldegrun, A. S., 1 Jul 2017, In: JAMA oncology. 3, 7, jamaoncol.2016.4419.

  Research output: Contribution to journal › Article › peer-review

  • Placebo 100%
  • Patient 66%
  • Clear Cell Renal Cell Carcinoma 58%
  • Renal Cell Carcinoma 58%
  • Overall Survival 41%

• CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo

  Kueberuwa, G., Gornall, H., Alcantar Orozco, E. M., Bouvier, D., Kapacee, Z. A., Hawkins, R. & Gilham, D., Dec 2017, In: Journal for ImmunoTherapy of Cancer. 5, 14

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chemokine Receptor 100%
  • T Cell 91%
  • Cells 41%
  • Differentiation 41%
  • Engraftment 25%

• CD19 CAR T-cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity

  Kueberuwa, G., Kalaitsidou, M., Cheadle, E., Hawkins, R. & Gilham, D., 2017, In: Molecular therapy oncolytics.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptor T-Cell 100%
  • Host 42%
  • Cell Therapy 28%
  • Immunocompetent Cell 28%
  • Lymphoma 28%

• Innovative regenerative medicines in the EU: A better future in evidence?

  Corbett, M. S., Webster, A., Hawkins, R. & Woolacott, N., 8 Mar 2017, In: BMC Medicine. 15, 1, 49.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Regenerative Medicine 100%
  • Patient 66%
  • Combination Therapy 66%
  • Clinical Practice 50%
  • Development 50%
• 2016

  High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

  Chow, S., Galvis, V., Pillai, M., Leach, R., Keene, E., Spencer-Shaw, A., Shablak, A., Shanks, J., Liptrot, T., Thistlethwaite, F. & Hawkins, R., 18 Oct 2016, In: Journal for ImmunoTherapy of Cancer. 4, 67

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Therapeutic Procedure 100%
  • Patient 80%
  • Pathology 40%
  • Experience 20%
  • Spontaneous Remission 20%

• Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

  Powles, T., Lackner, M. R., Oudard, S., Escudier, B., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., Ravaud, A., Lin, W., O'Keeffe, B., Wang, Y., Lu, S., Spoerke, J. M., Huw, L-Y., Byrtek, M., Zhu, R., Ware, J. A., & 1 othersMotzer, R. J., 10 May 2016, In: Journal of Clinical Oncology. 34, 14, p. 1660-8 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Everolimus 100%
  • Kidney Metastasis 40%
  • Mammalian Target of Rapamycin 40%
  • Biological Marker 20%
  • Adverse Event 20%

• Tumour–microenvironment mediates resistance to immuno and targeted therapies in acral melanoma

  Lee, R., Girotti, M. R., Khandelwal, G., Baenke, F., Viros, A., Mandal, A., Bridgeman, J., Galvani, E., Gremel, G., Kalaitsidou, M., Ashton, G., Peset, I., Smith, M., Hawkins, R., Fusi, A., Miller, C., Gilham, D., Dhomen, N., Lorigan, P. & Marais, R., Jul 2016, In: European Journal of Cancer. 61, p. S188

  Research output: Contribution to journal › Article › peer-review
• 2015

  Adoptive Cell Therapy for metastatic melanoma: A UK centre experience

  Pillai, M. R., Guest, R., Kirillova, N., Chow, S., Lorigan, P. & Hawkins, R. E., 2015, In: Journal of Clinical Oncology. 33, 15, p. 9060 1 p.

  Research output: Contribution to journal › Article › peer-review

• Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015

  Gilham, D. E., Anderson, J., Bridgeman, J. S., Hawkins, R. E., Exley, M. A., Stauss, H., Maher, J., Pule, M., Sewell, A. K., Bendle, G., Lee, S., Qasim, W., Thrasher, A. & Morris, E., 2015, In: Hum Gene Ther. 26, 5, p. 276-85 190 p.

  Research output: Contribution to journal › Article › peer-review

  • Malignant Neoplasm 100%
  • Clinical Study 33%
  • Preclinical Study 33%

• Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma

  Baldan, V., Griffiths, R., Hawkins, R. E. & Gilham, D. E., 2015, In: Br J Cancer. 112, 9, p. 1510-8 1501 p.

  Research output: Contribution to journal › Article › peer-review

  • Tumor Infiltrating Lymphocyte 100%
  • Neoplasm 75%
  • Clear Cell Renal Cell Carcinoma 50%
  • Recognition 37%
  • Biopsy 37%

• Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis.

  Flaum, N., Lorigan, P., Whitfield, G., Hawkins, R. E. & Pinkham, M., 22 Oct 2015, In: Practical Radiation Oncology . 6, 2, p. 376-378 2 p., j.prro.2015.10.008.

  Research output: Contribution to journal › Article › peer-review

• Overcoming the toxicity hurdles of geneticall targetted T Cells

  Casucci, M., Hawkins, RE., Dotti, G. & Bondanza, A., Jan 2015, In: Cancer Immunology, Immunotherapy. 64, 1, p. 123-130 7 p.

  Research output: Contribution to journal › Article › peer-review
• 2014

  Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review

  Oh, WK., McDermott, D., Porta, C., Levy, A., Elaidi, R., Scotte, F., Hawkins, R., Castellano, D., Bellmunt, J., Rha, SY., Sun, JM., Nathan, P., Feinberg, BA., Scott, J., McDermott, R., Ahn, JH., Wagstaff, J., Chang, YH., Ou, YC., Donnellan, P., & 9 othersHuang, CY., McCaffrey, J., Chiang, PH., Chuang, CK., Korves, C., Neary, MP., Diaz, JR., Mehmud, F. & Duh, MS., Nov 2014, In: International Journal of Oncology. 44, 1, p. 5-16 11 p.

  Research output: Contribution to journal › Article › peer-review

• An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.

  Sternberg, CN., Davis, ID., Deen, KC., Sigal, E. & Hawkins, RE., 6 Sep 2014, In: Oncology. 87, 6, p. 342-350 8 p.

  Research output: Contribution to journal › Article › peer-review

• CAR T cells: driving the road from the laboratory to the clinic

  Cheadle, E. J., Gornall, H., Baldan, V., Hanson, V., Hawkins, R. E. & Gilham, D. E., 2014, In: Immunological reviews. 257, 1, p. 91-106 16 p.

  Research output: Contribution to journal › Article › peer-review

  • Chimeric Antigen Receptor T-Cell 100%
  • T Cell 60%
  • Clinical Research 40%
  • Chimeric Antigen Receptor 40%
  • Patient 20%

• CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

  Bridgeman, JS., Ladell, K., Sheard, VE., Miners, K., Hawkins, RE., Price, DA. & Gilham, DE., Feb 2014, In: Clinical and experimental immunology. 175, 2, p. 258-267 9 p.

  Research output: Contribution to journal › Article › peer-review

• Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial

  Guest, R. D., Kirillova, N., Mowbray, S., Gornall, H., Rothwell, D. G., Cheadle, E. J., Austin, E., Smith, K., Watt, S. M., Kühlcke, K., Westwood, N., Thistlethwaite, F., Hawkins, R. E. & Gilham, D. E., 1 Feb 2014, In: Cancer Immunology, Immunotherapy. 63, 2, p. 133-145 12 p., 10.1007/s00262-013-1492-9.

  Research output: Contribution to journal › Article › peer-review

  • T Cell 100%
  • Chimeric Antigen Receptor T-Cell 66%
  • Chimeric Antigen Receptor 50%
  • Carcinoembryonic Antigen 50%
  • Clinical Trial 50%

• Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model

  Cheadle, E. J., Sheard, V., Rothwell, D. G., Bridgeman, J. S., Ashton, G., Hanson, V., Mansoor, A. W., Hawkins, R. E. & Gilham, D. E., 2014, In: J Immunol. 192, 8, p. 3654-65 12 p.

  Research output: Contribution to journal › Article › peer-review

  • T Cell 100%
  • Cytokine 50%
  • Serum 20%
  • Receptor 20%
  • B-Cell Lymphoma 20%

• High-dose interleukin 2-induced myocarditis: can myocardial damage reversibility be assessed by cardiac MRI?

  Chow, S., Cove-Smith, L., Schmitt, M. & Hawkins, R., Jun 2014, In: Journal of Immunotherapy. 37, 5, p. 304-308 4 p.

  Research output: Contribution to journal › Article › peer-review

• Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens

  Hayes, SJ., Hng, KN., Clark, P., Thistlethwaite, F., Hawkins, RE. & Ang, Y., 14 Apr 2014, In: World Journal of Gastroenterology. 20, 14, p. 4011-4016 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Esophageal Adenocarcinoma 100%
  • Specimen 60%
  • Adenocarcinoma 60%
  • Metaplasia 60%
  • Gland 60%

• Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

  Porta, C., Levy, A., Hawkins, R., Castellano, D., Bellmunt, J., Nathan, P., McDermott, R., Wagstaff, J., Donnellan, P., McCaffrey, J., Vekeman, F., Neary, MP., Diaz, J., Mehmud, F. & Duh, MS., Dec 2014, In: Cancer Medicine. 3, 6, p. 1517-1526 9 p.

  Research output: Contribution to journal › Article › peer-review

• In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.

  Shablak, A., Gilham, DE., Hawkins, RE. & Elkord, E., Aug 2014, In: Expert opinion on pharmacotherapy. 15, 11, p. 1489-1499 10 p.

  Research output: Contribution to journal › Article › peer-review

• Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.

  Eisen, T., Hedlund, G., Forsberg, G. & Hawkins, R., Feb 2014, In: Current Oncology Reports (Print). 16, 2, p. 370-371 1 p.

  Research output: Contribution to journal › Article › peer-review

• Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

  Escudier, B., Porta, C., Bono, P., Powles, T., Eisen, T., Sternberg, CN., Gschwend, JE., De, G. U., Parikh, O., Hawkins, R., Sevin, E., Négrier, S., Khan, S., Diaz, J., Redhu, S., Mehmud, F. & Cella, D., May 2014, In: Journal of Clinical Oncology. 32, 14, p. 1412-1418 6 p.

  Research output: Contribution to journal › Article › peer-review
• 2013

  A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

  Sternberg, CN., Hawkins, RE., Wagstaff, J., Salman, P., Mardiak, J., Barrios, CH., Zarba, JJ., Gladkov, OA., Lee, E., Szczylik, C., McCann, L., Rubin, SD., Chen, M. & Davis, ID., 2013, In: European Journal of Cancer. 49, 6, p. 1287-1296 9 p.

  Research output: Contribution to journal › Article › peer-review

• Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol.

  Lipowska-Bhalla, G., Gilham, DE., Hawkins, RE. & Rothwell, D. G., Dec 2013, In: Human Gene Therapy. Methods. 24, 6, p. 381-391 10 p.

  Research output: Contribution to journal › Article › peer-review

• Pazopanib versus sunitinib in metastatic renal-cell carcinoma

  Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., Souza, P., Merchan, J. R., Boleti, E., Fife, K., Jin, J., Jones, R., Uemura, H., De Giorgi, U., Harmenberg, U., Wang, J., Sternberg, C. N., Deen, K., & 5 othersMcCann, L., Hackshaw, M. D., Crescenzo, R., Pandite, L. N. & Choueiri, T. K., 2013, In: New England Journal Of Medicine. 369, 8, p. 722-731 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Pazopanib 100%
  • Sunitinib 100%
  • Progression Free Survival 50%
  • Kidney Metastasis 50%
  • Interferon 16%
• 2012

  Cancer classification using the Immunoscore: A worldwide task force

  Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C., Botti, G., Tatangelo, F., Britten, C. M., Kreiter, S., Chouchane, L., Delrio, P., Arndt, H., Asslaber, M., Maio, M., Masucci, G. V., Mihm, M., & 44 othersVidal-Vanaclocha, F., Allison, J. P., Gnjatic, S., Hakansson, L., Huber, C., Singh-Jasuja, H., Ottensmeier, C., Zwierzina, H., Laghi, L., Grizzi, F., Ohashi, P. S., Shaw, P. A., Clarke, B. A., Wouters, B. G., Kawakami, Y., Hazama, S., Okuno, K., Wang, E., O'Donnell-Tormey, J., Lagorce, C., Pawelec, G., Nishimura, M. I., Hawkins, R., Lapointe, R., Lundqvist, A., Khleif, S. N., Ogino, S., Gibbs, P., Waring, P., Sato, N., Torigoe, T., Itoh, K., Patel, P. S., Shukla, S. N., Palmqvist, R., Nagtegaal, I. D., Wang, Y., D'Arrigo, C., Kopetz, S., Sinicrope, F. A., Trinchieri, G., Gajewski, T. F., Ascierto, P. A. & Fox, B. A., 3 Oct 2012, In: Journal of Translational Medicine. 10, 1, 205.

  Research output: Contribution to journal › Article › peer-review

  • Malignant Neoplasm 100%
  • Classification 100%
  • Neoplasm 75%
  • Cancer Staging 75%
  • Patient 50%

• CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe

  Gilham, D. E., Debets, R., Pule, M., Hawkins, R. E. & Abken, H., Jul 2012, In: Trends in molecular medicine. 18, 7, p. 377-384 7 p.

  Research output: Contribution to journal › Article › peer-review

  • T Cell 100%
  • Chimeric Antigen Receptor T-Cell 80%
  • Neoplasm 40%
  • Chimeric Antigen Receptor 40%
  • Cell Therapy 20%

• Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

  Mulders, P., Hawkins, R., Nathan, P., De Jong, I., Osanto, S., Porfiri, E., Protheroe, A., Van Herpen, C. M. L., Mookerjee, B., Pike, L., Jürgensmeier, J. M. & Gore, M. E., Mar 2012, In: European Journal of Cancer. 48, 4, p. 527-537 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Cediranib 100%
  • Placebo 50%
  • Renal Cell Carcinoma 25%
  • Progression Free Survival 25%
  • Diseases 16%

• Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: A randomised phase II study

  Roy, A., Cunningham, D., Hawkins, R., Sörbye, H., Adenis, A., Barcelo, J. R., Lopez-Vivanco, G., Adler, G., Canon, J. L., Lofts, F., Castanon, C., Fonseca, E., Rixe, O., Aparicio, J., Cassinello, J., Nicolson, M., Mousseau, M., Schalhorn, A., D'Hondt, L., Kerger, J., & 5 othersHossfeld, D. K., Garcia Giron, C., Rodriguez, R., Schoffski, P. & Misset, J. L., 24 Jul 2012, In: British Journal of Cancer. 107, 3, p. 435-441 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Docetaxel 100%
  • Chemotherapy 66%
  • Stomach Cancer 66%
  • Patient 50%
  • Irinotecan 50%

• Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges

  Lipowska-Bhalla, G., Gilham, D. E., Hawkins, R. E. & Rothwell, D. G., Jul 2012, In: Cancer Immunology, Immunotherapy. 61, 7, p. 953-962 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Chimeric Antigen Receptor 100%
  • Immunotherapy 74%
  • Chimeric Antigen Receptor T-Cell 50%
  • Gene 25%
  • Cells 25%
• 2011

  An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

  Bodrogi, I. & The REACT Study Group, 29 Jul 2011, In: Eur J Cancer.

  Research output: Contribution to journal › Article › peer-review

• Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs

  Elkord, E., Sharma, S., Burt, D. J. & Hawkins, R. E., Sep 2011, In: Clinical Immunology. 140, 3, p. 218-222 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Regulatory T Cell 100%
  • Clear Cell Renal Cell Carcinoma 40%
  • Carcinoma Cell 40%
  • Patient 30%
  • Interleukin 2 20%

• High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer

  Shablak, A., Sikand, K., Shanks, J. H., Thistlethwaite, F., Spencer-Shaw, A. & Hawkins, R. E., Jan 2011, In: Journal of Immunotherapy. 34, 1, p. 107-112 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Patient 100%
  • Drug Megadose 87%
  • Interleukin 2 87%
  • Therapeutic Procedure 75%
  • Spontaneous Remission 50%

• Ligation of CD2 co-stimulatory receptor enhances IL-2 production from first generation chimeric antigen receptor T cells

  Cheadle, EJ., Rothwell, DG., Bridgeman, JS., Sheard, VE., Hawkins, RE. & Gilham, DE., Dec 2011, In: Gene Ther.

  Research output: Contribution to journal › Article › peer-review

• Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: A lesson from two cases

  Shablak, A., O'Dwyer, J., Hawkins, R. & Board, R., Mar 2011, In: Urologia Internationalis. 86, 2, p. 245-248 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Sunitinib 100%
  • Therapeutic Procedure 75%
  • Metastatic Carcinoma 75%
  • Patient 50%
  • Kidney Metastasis 50%

• MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients

  Harrop, R., Shingler, W. H., McDonald, M., Treasure, P., Amato, R. J., Hawkins, R. E., Kaufman, H. L., De Belin, J., Kelleher, M., Goonewardena, M. & Naylor, S., Jun 2011, In: Cancer Immunology, Immunotherapy. 60, 6, p. 829-837 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Patient 100%
  • Therapeutic Procedure 66%
  • Antibody Response 66%
  • Immune Response 50%
  • Kidney Cancer 50%

• Sunitinib in metastatic renal cell carcinoma patients with brain metastases

  Gore, M. E., Hariharan, S., Porta, C., Bracarda, S., Hawkins, R., Bjarnason, G. A., Oudard, S., Lee, S. H., Carteni, G., Nieto, A., Yuan, J. & Szczylik, C., 1 Feb 2011, In: Cancer. 117, 3, p. 501-509 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Patient 100%
  • Sunitinib 100%
  • Kidney Metastasis 66%
  • Brain Metastasis 66%
  • Therapeutic Procedure 50%
• 2010

  Amplification of epidermal growth factor receptor gene in renal cell carcinoma

  El-Hariry, I., Powles, T., Lau, M. R., Sternberg, C. N., Ravaud, A., von der Maase, H., Zantl, N., Harper, P., Rolland, F., Audhuy, B., Barthel, F., Machiels, J. P., Patel, P., Kreuser, E. D. & Hawkins, R. E., Mar 2010, In: European Journal of Cancer. 46, 5, p. 859-862 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Cancer Cell 100%
  • Epidermal Growth Factor Receptor 100%
  • Gene Amplification 100%
  • Patient 66%
  • Clear Cell Renal Cell Carcinoma 33%

• A phase I/II study of siltuximab (CNTO) an anti-interleukin-6 monoclonal antibody in metastatic renal cell cancer

  Rossi, JF., Negrier, S., James, ND., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P. & Berns, B., 2010, In: Br J Cancer. 38, 6, p. 1154-1162 8 p.

  Research output: Contribution to journal › Article › peer-review